Crucell reports early-stage success with TB vaccine

Shares of Crucell jumped after the developer announced that an early-stage trial of an experimental tuberculosis vaccine demonstrated a promising immune response in volunteers. The Dutch biotech is teamed up with the Aeras Global TB Vaccine Foundation and the South African Tuberculosis Vaccine Initiative in advancing AERAS-402/Crucell Ad35. And a third early-stage vaccine trial is underway in South Africa, which has an extraordinarily high rate of the disease. The currently used vaccine, Bacille Calmette-Guerin, was developed 85 years ago, but is regarded as largely ineffective against pulmonary TB.

"While preliminary, these results are promising. We are pleased that Crucell's technologies are playing a key role in the search and development of a much-needed TB vaccine," said Dr. Jaap Goudsmit, chief scientific officer at Crucell. "We highly value the collaboration with Aeras and SATVI on this important mission."

- see the release
- read this report

Related Articles:
In surprise move, Crucell dumps West Nile program
Crucell, MedImmune strike deal
Crucell acquires SBL Vaccin for €39.4M. Report

Suggested Articles

Merck & Co. inked a series of deals to advance three COVID-19 projects, trailing some of its large pharma peers into the industrywide research effort.

With a new £131 million contribution from the U.K. government, VMIC aims to both speed up and expand on its prior ambitions.

AstraZeneca scored a $1 billion contribution from the United States for development, production and delivery of its potential COVID-19 vaccine.